Blockchain Registration Transaction Record

Oncotelic's Nanomedicine Cuts Drug Side Effects by 67-Fold

Oncotelic Therapeutics unveils nanomedicine platform cutting drug side effects by 67-fold. Learn how Deciparticle™ transforms oncology and immunology treatments with IV-ready nanoparticles.

This news matters because it represents a potential leap forward in cancer and immunology treatments. Traditional oral medications like Everolimus often cause severe gastrointestinal issues due to drug accumulation, limiting patient tolerance and effectiveness. By reducing this accumulation by up to 67-fold through intravenous nanomedicine delivery, Oncotelic's technology could significantly improve patient outcomes—allowing for higher, more effective doses with fewer side effects. In oncology, where treatment adherence and quality of life are critical, such advancements could lead to better survival rates and reduced hospitalizations. For the broader medical field, this scalable nanotechnology platform opens doors to reformulating other hard-to-deliver drugs, potentially accelerating development of new therapies for various diseases. Investors and patients alike should watch this space, as it could disrupt current treatment standards and offer new hope where conventional methods fall short.